HRP20220884T1 - Proteini specifični za baff i b7rp1 i njihova uporaba - Google Patents
Proteini specifični za baff i b7rp1 i njihova uporaba Download PDFInfo
- Publication number
- HRP20220884T1 HRP20220884T1 HRP20220884TT HRP20220884T HRP20220884T1 HR P20220884 T1 HRP20220884 T1 HR P20220884T1 HR P20220884T T HRP20220884T T HR P20220884TT HR P20220884 T HRP20220884 T HR P20220884T HR P20220884 T1 HRP20220884 T1 HR P20220884T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- host cell
- acid sequence
- seq
- cell according
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 13
- 108090000623 proteins and genes Proteins 0.000 title claims 13
- 210000004027 cell Anatomy 0.000 claims 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 230000009466 transformation Effects 0.000 claims 3
- 210000005253 yeast cell Anatomy 0.000 claims 3
- 241000238631 Hexapoda Species 0.000 claims 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 2
- 102100034980 ICOS ligand Human genes 0.000 claims 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 238000000844 transformation Methods 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Claims (17)
1. Stanica domaćina koja sadrži nukleinsku kiselinu koja kodira bispecifični protein, i/ili vektor koji sadrži nukleinsku kiselinu koja kodira bispecifični protein, naznačena time što bispecifični protein sadrži:
(a) polipeptid koji sadrži aminokiselinsku sekvencu koja ima sljedeću formulu:
A-L1-P-L2-P, pri čemu je A imunoglobulinski teški lanac IgG protutijela, L1 je prva peptidna poveznica koja je odsutna ili je dugačka 3 do 40 aminokiselina, P je BAFF-vezujući peptid koji je dug 10 do 40 aminokiselina, i L2 je druga peptidna poveznica koja je odsutna ili je dugačka 5 do 50 aminokiselina, i
(b) laki lanac imunoglobulina IgG protutijela,
pri čemu imunoglobulinski teški lanac (a) i imunoglobulinski laki lanac (b) tvore IgG protutijelo, koje se sastoji od dvije molekule polipeptida (a) i dvije molekule lakog lanca (b), koje može vezati B7RP1, i
pri čemu protein može inhibirati BAFF-om posredovanu proliferaciju ljudskih B stanica, i
pri čemu protein može inhibirati B7RP1- posredovanu proliferaciju ljudskih T stanica, i
pri čemu je stanica domaćin bakterijska stanica, stanica kvasca, stanica insekta, biljna stanica ili stanica sisavca.
2. Stanica domaćin prema zahtjevu 1, naznačena time što bispecifični protein sadrži teški lanac imunoglobulina kojemu nedostaje lizin na C-terminalnom kraju odmah uzvodno od L1.
3. Stanica domaćin prema zahtjevu 1, naznačena time što je IgG protutijelo je ljudsko ili humanizirano anti-B7RP1 IgG1 protutijelo.
4. Stanica domaćin prema zahtjevu 1 ili 2, naznačena time što je anti-B7RP1 protutijelo ljudsko ili humanizirano IgG2 protutijelo, ili ljudsko ili humanizirano IgG4 protutijelo.
5. Stanica domaćin prema bilo kojem od zahtjeva 1-4, naznačena time što P ima sekvencu aminokiselina SEQ ID NO:1 (LPGCKWDLLIKQWVCDPL).
6. Stanica domaćin prema bilo kojem od zahtjeva 1-5, naznačena time što L1 ima aminokiselinsku sekvencu SEQ ID NO:40 (GGGGG).
7. Stanica domaćin prema bilo kojem od zahtjeva 1-6, naznačena time što L2 ima aminokiselinsku sekvencu SEQ ID NO:5, poželjno pri čemu L2 ima aminokiselinsku sekvencu SEQ ID NO:6 ili SEQ ID NO:7.
8. Stanica domaćin prema bilo kojem od zahtjeva 1-7, naznačena time što kodira CDR1 lakog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:8 (RASQGISNWLA), CDR2 lakog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:9 (AASSLQS), CDR3 lakog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:10 (QQYDSYPRT) , CDR1 teškog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:11 (SYWMS), CDR2 teškog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:12 (YIKQDGNEKYYVDSVKG), i CDR3 teškog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:13 (EGILWFGDLPTF).
9. Stanica domaćin prema bilo kojem od zahtjeva 1-8, naznačena time što kodirani bispecifični protein sadrži varijabilnu regiju lakog lanca imunoglobulina koja sadrži aminokiselinsku sekvencu SEQ ID NO:14.
10. Stanica domaćin prema bilo kojem od zahtjeva 1-9, naznačena time što kodirani bispecifični protein sadrži varijabilnu regiju teškog lanca imunoglobulina koja sadrži aminokiselinsku sekvencu SEQ ID NO:15.
11. Stanica domaćin prema bilo kojem od zahtjeva 5-10, naznačena time što laki lanac imunoglobulina iz (b) sadrži aminokiselinsku sekvencu SEQ ID NO:19.
12. Stanica domaćin prema bilo kojem od zahtjeva 5-11, naznačena time što polipeptid iz (a) sadrži aminokiselinsku sekvencu SEQ ID NO:17 ili 18.
13. Stanica domaćin prema zahtjevu 1, naznačena time što polipeptid (a) sadrži aminokiselinsku sekvencu SEQ ID NO:17 ili SEQ ID NO:18, a polipeptid (b) sadrži aminokiselinsku sekvencu SEQ ID NO:19.
14. Stanica domaćin prema zahtjevu 1, naznačena time što bispecifični protein sadrži aminokiselinske sekvence SEQ ID NO:1, SEQ ID NO:14 i SEQ ID NO:15, poželjno, pri čemu protein nadalje sadrži poveznicu koja sadrži aminokiselinsku sekvencu SEQ ID NO:6 ili SEQ ID NO:7.
15. Stanica domaćin prema bilo kojem od zahtjeva 1-14, naznačena time što je stanica domaćin stanica sisavca odabrana iz skupine koju čine stanica jajnika kineskog hrčka (CHO), stanica bubrega bebe hrčka (BHK), stanica bubrega majmuna, stanica HeLa, stanica ljudskog hepatocelularnog karcinoma i stanica 293.
16. Postupak za izradu bispecifičnog proteina koji uključuje uzgoj stanice domaćina prema bilo kojem od zahtjeva 1-14 pod takvim uvjetima da se eksprimira nukleinska kiselina i obnavljanje proteina iz stanične mase ili medija kulture, pri čemu je stanica domaćin bakterijska stanica, stanica kvasca, stanica insekta ili biljna stanica.
17. Postupak prema zahtjevu 16, naznačena time što se nukleinska kiselina ili vektor uvodi u stanicu pomoću
(a) elektroporacije ili transformacije kalcijevim kloridom, pri čemu je stanica domaćin bakterijska stanica, ili
(b) transformacije litijevim acetatom ili transformacije polietilen glikolom, pri čemu je stanica domaćin stanica kvasca.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780260P | 2013-03-13 | 2013-03-13 | |
US201461942776P | 2014-02-21 | 2014-02-21 | |
EP18182864.1A EP3456344B1 (en) | 2013-03-13 | 2014-03-12 | Proteins specific for baff and b7rp1 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220884T1 true HRP20220884T1 (hr) | 2022-10-14 |
Family
ID=50483540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220884TT HRP20220884T1 (hr) | 2013-03-13 | 2014-03-12 | Proteini specifični za baff i b7rp1 i njihova uporaba |
HRP20181629TT HRP20181629T1 (hr) | 2013-03-13 | 2018-10-10 | Proteini specifični za baff i b7rp1 i njihove upotrebe |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181629TT HRP20181629T1 (hr) | 2013-03-13 | 2018-10-10 | Proteini specifični za baff i b7rp1 i njihove upotrebe |
Country Status (36)
Country | Link |
---|---|
US (3) | US10421823B2 (hr) |
EP (3) | EP3456344B1 (hr) |
JP (2) | JP6523243B2 (hr) |
KR (2) | KR102361632B1 (hr) |
CN (2) | CN110437336A (hr) |
AP (1) | AP2015008768A0 (hr) |
AU (1) | AU2014244498B2 (hr) |
CA (1) | CA2904992C (hr) |
CL (1) | CL2015002600A1 (hr) |
CR (1) | CR20150544A (hr) |
CY (1) | CY1120569T1 (hr) |
DK (2) | DK2968491T3 (hr) |
EA (1) | EA035388B1 (hr) |
ES (2) | ES2923909T3 (hr) |
HK (1) | HK1218885A1 (hr) |
HR (2) | HRP20220884T1 (hr) |
HU (2) | HUE059507T2 (hr) |
IL (1) | IL241281B (hr) |
JO (2) | JOP20140087B1 (hr) |
LT (2) | LT2968491T (hr) |
MX (2) | MX369502B (hr) |
MY (2) | MY171938A (hr) |
NZ (2) | NZ751502A (hr) |
PE (1) | PE20151772A1 (hr) |
PH (1) | PH12015502074A1 (hr) |
PL (2) | PL3456344T3 (hr) |
PT (2) | PT3456344T (hr) |
RS (2) | RS63431B1 (hr) |
SG (1) | SG11201507208VA (hr) |
SI (2) | SI3456344T1 (hr) |
TN (1) | TN2015000414A1 (hr) |
TW (1) | TWI603978B (hr) |
UA (1) | UA120034C2 (hr) |
UY (1) | UY35396A (hr) |
WO (1) | WO2014159725A1 (hr) |
ZA (1) | ZA201506708B (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2446189C (en) * | 2001-05-11 | 2011-10-18 | Amgen, Inc. | Peptides and related molecules that bind to tall-1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) * | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
ITUB20151014A1 (it) | 2015-05-27 | 2016-11-27 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
WO2020027224A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人東京大学 | 新たな結合特異性を抗体に付与する超汎用法 |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
CA2111348A1 (en) | 1991-06-14 | 1992-12-23 | John S. Logan | Production of human hemoglobin in transgenic pigs |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
AU7568094A (en) | 1993-08-12 | 1995-03-14 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
DE4435919C1 (de) | 1994-10-07 | 1995-12-07 | Deutsches Krebsforsch | Zinkfinger-DNA, -Protein und ihre Verwendung |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
CA2222550A1 (en) | 1995-06-07 | 1996-12-19 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
ATE302272T1 (de) | 1996-10-25 | 2005-09-15 | Human Genome Sciences Inc | Neutrokin alpha |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
IL133316A0 (en) | 1997-06-06 | 2001-04-30 | Regeneron Pharma | Ntn-2 member of tnf ligand family |
JP2002504818A (ja) | 1997-06-06 | 2002-02-12 | リジェネロン ファーマシューティカルズ,インコーポレイテッド | リガンドファミリーのntn−2メンバー |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
HUP0004034A3 (en) | 1997-09-12 | 2002-08-28 | Apotech R & D Sa | Kay - a novel immune system protein |
CA2305350C (en) | 1997-09-23 | 2015-04-07 | Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts | Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof |
DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
AU2212299A (en) | 1998-01-05 | 1999-07-26 | Genentech Inc. | Compositions and methods for the treatment of tumor |
WO1999062951A1 (en) | 1998-06-04 | 1999-12-09 | Shanghai Second Medical University | A human zinc finger protein gene (bmzf3) |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ATE437227T1 (de) | 1999-01-07 | 2009-08-15 | Zymogenetics Inc | Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2 |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
CZ299819B6 (cs) | 1999-01-25 | 2008-12-03 | Biogen Idec Ma Inc. | Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF |
NZ551331A (en) | 1999-02-03 | 2008-08-29 | Amgen Inc | Methods using polypeptides involved in immune response |
US7708993B2 (en) | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
AU2880400A (en) | 1999-02-12 | 2000-08-29 | Amgen, Inc. | Tnf-related proteins |
IL145134A0 (en) | 1999-03-25 | 2002-06-30 | Knoll Gmbh | Human antibodies that bind human il-12 and methods for producing |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
AU4986700A (en) | 1999-05-06 | 2000-11-21 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
IL147270A0 (en) | 1999-07-02 | 2002-08-14 | Genentech Inc | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
AU6458400A (en) | 1999-08-11 | 2001-03-13 | Isis Innovation Limited | Nucleic acid, polypeptides, assays, therapeutic methods and means |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
ATE366814T1 (de) | 1999-09-21 | 2007-08-15 | Genetics Inst Llc | Gl50 moleküle, sowie verwendungen derselben |
EP1900816A3 (en) | 1999-09-21 | 2008-03-26 | Genetics Institute, LLC | GL50 molecules and uses therefor |
AU3695801A (en) | 2000-02-11 | 2001-11-20 | Amgen, Inc. | Receptor from tnf family |
AU2001245396A1 (en) | 2000-03-02 | 2001-09-12 | Mayo Foundation For Medical Education And Research | Hb7-h2, a novel co-stimulatory molecule |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
NZ522700A (en) | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
GB0016633D0 (en) | 2000-07-07 | 2000-08-23 | Bp Exploration Operating | Process |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
DE60140773D1 (de) | 2000-08-18 | 2010-01-21 | Dyax Corp | Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS) |
WO2002016411A2 (en) | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
JP4236925B2 (ja) | 2000-11-28 | 2009-03-11 | アムジエン・インコーポレーテツド | 免疫応答に関与する新規ポリペプチド |
CA2435037A1 (en) | 2001-01-18 | 2002-07-25 | Silke Schumacher | Bifunctional fusion proteins with glucocerebrosidase activity |
CA2446189C (en) | 2001-05-11 | 2011-10-18 | Amgen, Inc. | Peptides and related molecules that bind to tall-1 |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
AU2003295411A1 (en) | 2002-11-07 | 2004-06-03 | Celltech R & D | Human monoclonal antibodies to heparanase |
CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
JP2006517191A (ja) | 2002-12-30 | 2006-07-20 | アムジエン・インコーポレーテツド | 共刺激因子を用いた併用療法 |
DE602004025101D1 (de) | 2003-05-31 | 2010-03-04 | Micromet Ag | Humane anti-humane cd3-bindungsmoleküle |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
WO2006003999A1 (ja) | 2004-07-05 | 2006-01-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント |
EP1773400A2 (en) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
EP1797127B1 (en) | 2004-09-24 | 2017-06-14 | Amgen Inc. | Modified fc molecules |
JP5142998B2 (ja) * | 2005-07-18 | 2013-02-13 | アムジエン・インコーポレーテツド | ヒト抗b7rp1中和抗体 |
AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
WO2008119042A2 (en) | 2007-03-27 | 2008-10-02 | Zymogenetics, Inc. | Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease |
CL2008002092A1 (es) | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
WO2009015345A1 (en) * | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
WO2009052293A1 (en) | 2007-10-16 | 2009-04-23 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
SG10201605629VA (en) | 2008-01-03 | 2016-08-30 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) * | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
CA2907181C (en) | 2013-03-15 | 2023-10-17 | Viktor Roschke | Multivalent and monovalent multispecific complexes and their uses |
CN105873949A (zh) | 2014-01-31 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 新的抗baff抗体 |
-
2014
- 2014-03-11 JO JOP/2014/0087A patent/JOP20140087B1/ar active
- 2014-03-12 HU HUE18182864A patent/HUE059507T2/hu unknown
- 2014-03-12 EP EP18182864.1A patent/EP3456344B1/en active Active
- 2014-03-12 CN CN201910521740.2A patent/CN110437336A/zh active Pending
- 2014-03-12 MY MYPI2015703088A patent/MY171938A/en unknown
- 2014-03-12 UA UAA201508877A patent/UA120034C2/uk unknown
- 2014-03-12 PT PT181828641T patent/PT3456344T/pt unknown
- 2014-03-12 US US14/776,399 patent/US10421823B2/en active Active
- 2014-03-12 JP JP2016501678A patent/JP6523243B2/ja active Active
- 2014-03-12 EA EA201591720A patent/EA035388B1/ru unknown
- 2014-03-12 AP AP2015008768A patent/AP2015008768A0/xx unknown
- 2014-03-12 SG SG11201507208VA patent/SG11201507208VA/en unknown
- 2014-03-12 KR KR1020217004604A patent/KR102361632B1/ko active IP Right Grant
- 2014-03-12 ES ES18182864T patent/ES2923909T3/es active Active
- 2014-03-12 KR KR1020157027042A patent/KR102218723B1/ko active IP Right Grant
- 2014-03-12 DK DK14717310.8T patent/DK2968491T3/en active
- 2014-03-12 SI SI201431972T patent/SI3456344T1/sl unknown
- 2014-03-12 EP EP20158997.5A patent/EP3689371A1/en active Pending
- 2014-03-12 SI SI201430908T patent/SI2968491T1/sl unknown
- 2014-03-12 EP EP14717310.8A patent/EP2968491B1/en active Active
- 2014-03-12 NZ NZ751502A patent/NZ751502A/en unknown
- 2014-03-12 PE PE2015001973A patent/PE20151772A1/es unknown
- 2014-03-12 CA CA2904992A patent/CA2904992C/en active Active
- 2014-03-12 LT LTEP14717310.8T patent/LT2968491T/lt unknown
- 2014-03-12 MY MYPI2018002384A patent/MY198370A/en unknown
- 2014-03-12 HU HUE14717310A patent/HUE040169T2/hu unknown
- 2014-03-12 PT PT14717310T patent/PT2968491T/pt unknown
- 2014-03-12 MX MX2015012440A patent/MX369502B/es active IP Right Grant
- 2014-03-12 RS RS20220711A patent/RS63431B1/sr unknown
- 2014-03-12 ES ES14717310.8T patent/ES2687299T3/es active Active
- 2014-03-12 UY UY0001035396A patent/UY35396A/es active IP Right Grant
- 2014-03-12 RS RS20181088A patent/RS57689B1/sr unknown
- 2014-03-12 WO PCT/US2014/024908 patent/WO2014159725A1/en active Application Filing
- 2014-03-12 DK DK18182864.1T patent/DK3456344T3/da active
- 2014-03-12 TW TW103108956A patent/TWI603978B/zh active
- 2014-03-12 LT LTEP18182864.1T patent/LT3456344T/lt unknown
- 2014-03-12 PL PL18182864.1T patent/PL3456344T3/pl unknown
- 2014-03-12 AU AU2014244498A patent/AU2014244498B2/en active Active
- 2014-03-12 HR HRP20220884TT patent/HRP20220884T1/hr unknown
- 2014-03-12 CN CN201480020434.6A patent/CN105324127B/zh active Active
- 2014-03-12 NZ NZ711954A patent/NZ711954A/en unknown
- 2014-03-12 PL PL14717310T patent/PL2968491T3/pl unknown
-
2015
- 2015-09-07 IL IL241281A patent/IL241281B/en active IP Right Grant
- 2015-09-10 ZA ZA2015/06708A patent/ZA201506708B/en unknown
- 2015-09-11 PH PH12015502074A patent/PH12015502074A1/en unknown
- 2015-09-11 MX MX2019013442A patent/MX2019013442A/es unknown
- 2015-09-11 TN TN2015000414A patent/TN2015000414A1/en unknown
- 2015-09-11 CL CL2015002600A patent/CL2015002600A1/es unknown
- 2015-10-13 CR CR20150544A patent/CR20150544A/es unknown
-
2016
- 2016-06-17 HK HK16106993.6A patent/HK1218885A1/zh unknown
-
2018
- 2018-08-09 CY CY20181100835T patent/CY1120569T1/el unknown
- 2018-10-10 HR HRP20181629TT patent/HRP20181629T1/hr unknown
-
2019
- 2019-04-25 JP JP2019084291A patent/JP6825033B2/ja active Active
- 2019-09-23 US US16/579,321 patent/US11492417B2/en active Active
-
2021
- 2021-01-12 JO JOP/2021/0010A patent/JOP20210010A1/ar unknown
-
2022
- 2022-09-28 US US17/936,062 patent/US20230128444A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
HRP20220884T1 (hr) | Proteini specifični za baff i b7rp1 i njihova uporaba | |
HRP20191704T1 (hr) | Multispecifična protutijela | |
HRP20200382T1 (hr) | Humanizirana ili kimerna protutijela cd3 | |
HRP20200189T1 (hr) | Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije | |
HRP20201031T1 (hr) | Anti-ctla-4 protutijela i postupci njihove upotrebe | |
HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
HRP20201191T1 (hr) | Mutirani multispecifični fab fragmenti antitijela | |
HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
HRP20201259T1 (hr) | Protutijela protiv ox40 i njihova upotreba | |
HRP20201993T1 (hr) | Protutijela protiv pd-1 | |
HRP20201090T1 (hr) | Protutijela anti-icos | |
HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
HRP20210364T1 (hr) | Anti-gitr antitijela i postupci za njihovu primjenu | |
HRP20210372T1 (hr) | Anti-lag3 antitijela i antigen-vezujući fragmenti | |
HRP20201747T1 (hr) | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 | |
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
HRP20180243T1 (hr) | Dvostruko specifične vezivne molekule antigena za aktivaciju t stanica | |
MX2014001883A (es) | Proteinas y peptidos modificados. | |
HRP20220107T1 (hr) | Proteini koji vežu kalikrein plazme | |
HRP20220787T1 (hr) | Protutijela protiv garp-tgf-beta | |
HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba |